3 M&A Stories to Watch Today

Bristol-Myers Squibb should be able to close its deal with Celgene now

Aug 26, 2019 at 10:28 AM
facebook twitter linkedin


Digesting this morning's market headlines, there are three M&A stories traders should be following. For starters, Bristol-Myers Squibb Co (NYSE:BMY) and Celgene Corporation (NASDAQ:CELG) are both making strong moves higher, thanks to news Amgen Inc (NASDAQ:AMGN) is buying CELG's psoriasis drug Otezla for $13.4 billion, paving the way for BMY and CELG's buyout deal. BMY is up 3.1% at $48.04, and CELG shares have added 3.1%, last seen at $96.94.

Meanwhile, Pitney Bowes Inc. (NYSE:PBI) is trading 5.3% higher at $3.80, after the company said it's selling its software solutions business for $700 million. The shipping company's stock has been destroyed in the past year, falling from the $8 area a year ago and touching its lowest point since the early 1980s earlier this month.

The last name to mention here is PDC Energy Inc (NASDAQ:PDCE), which is buying SRC Energy (SRCI) for $971 million in stock. Analysts at Williams Capital weighed in and said the transaction is "logical." PDCE shares are up 16.6% this morning at $29.44, though this still leaves them down 45% in the past year.

 

Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 

 


 


 
Special Offers from Schaeffer's Trading Partners